Neurocytoskeleton Proteins in Cerebrospinal Fluid of People With HIV-1 Subtypes B and C.
Journal
Journal of acquired immune deficiency syndromes (1999)
ISSN: 1944-7884
Titre abrégé: J Acquir Immune Defic Syndr
Pays: United States
ID NLM: 100892005
Informations de publication
Date de publication:
15 08 2020
15 08 2020
Historique:
entrez:
22
7
2020
pubmed:
22
7
2020
medline:
12
3
2021
Statut:
ppublish
Résumé
The objective was to compare the effect of HIV-1C and HIV-1B subtypes on neurofilament light (NfL) cerebrospinal fluid (CSF) levels and ratios of NfL to tau proteins. Additional comparisons were performed between people with HIV (PWH), participants with Alzheimer disease (AD), and HIV-negative controls (HIV-). We also calculated the diagnostic characteristics of CSF NfL and its ratios in HIV-associated neurocognitive disorder (HAND) diagnosis. CSF NfL, T-tau, and P-tau181 concentrations were measured using immunoassays in a total of 108 CSF samples, including PWH (n = 68), HIV- (n = 16), and participants with AD (n = 24). These proteins were compared between HIV-1B (n = 27) and HIV-1C (n = 26) using multiple linear regression adjusted for nadir CD4 and plasma viral load suppression. Comparisons between PWH, HIV-, and participants with AD were adjusted for gender and age. CSF neurocytoskeleton proteins and their ratios were comparable in HIV-1B and HIV-1C. However, the HIV-1C group had a higher proportion of samples of CSF NfL above the reference value (n = 14, 53.85%) than the HIV-1B group (n = 8, 29.63%), P = 0.098. The values of CSF NfL were higher in the AD group [2578 (1864; 3500) pg/mL] than those in PWH [683 (500; 1197) pg/mL, P < 0.001] and control [660 (539; 802) pg/mL, P = 0.012] groups. The value of CSF NfL and its ratios for HAND diagnosis were poor. The effects of HIV-1B and HIV-1C on CSF NfL and tau ratios were comparable. The differences in CSF neurocytoskeleton proteins between PWH and individuals with AD suggested they might not share the same mechanisms of impairment. Further research is necessary to evaluate CSF NfL on the differential diagnoses of HAND with AD.
Sections du résumé
BACKGROUND
The objective was to compare the effect of HIV-1C and HIV-1B subtypes on neurofilament light (NfL) cerebrospinal fluid (CSF) levels and ratios of NfL to tau proteins. Additional comparisons were performed between people with HIV (PWH), participants with Alzheimer disease (AD), and HIV-negative controls (HIV-). We also calculated the diagnostic characteristics of CSF NfL and its ratios in HIV-associated neurocognitive disorder (HAND) diagnosis.
METHODS
CSF NfL, T-tau, and P-tau181 concentrations were measured using immunoassays in a total of 108 CSF samples, including PWH (n = 68), HIV- (n = 16), and participants with AD (n = 24). These proteins were compared between HIV-1B (n = 27) and HIV-1C (n = 26) using multiple linear regression adjusted for nadir CD4 and plasma viral load suppression. Comparisons between PWH, HIV-, and participants with AD were adjusted for gender and age.
RESULTS
CSF neurocytoskeleton proteins and their ratios were comparable in HIV-1B and HIV-1C. However, the HIV-1C group had a higher proportion of samples of CSF NfL above the reference value (n = 14, 53.85%) than the HIV-1B group (n = 8, 29.63%), P = 0.098. The values of CSF NfL were higher in the AD group [2578 (1864; 3500) pg/mL] than those in PWH [683 (500; 1197) pg/mL, P < 0.001] and control [660 (539; 802) pg/mL, P = 0.012] groups. The value of CSF NfL and its ratios for HAND diagnosis were poor.
CONCLUSION
The effects of HIV-1B and HIV-1C on CSF NfL and tau ratios were comparable. The differences in CSF neurocytoskeleton proteins between PWH and individuals with AD suggested they might not share the same mechanisms of impairment. Further research is necessary to evaluate CSF NfL on the differential diagnoses of HAND with AD.
Identifiants
pubmed: 32692110
doi: 10.1097/QAI.0000000000002389
pii: 00126334-202008150-00010
pmc: PMC8544917
mid: NIHMS1744804
doi:
Substances chimiques
Biomarkers
0
Cytoskeletal Proteins
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
514-521Subventions
Organisme : NIAID NIH HHS
ID : P30 AI036214
Pays : United States
Organisme : NIMH NIH HHS
ID : P30 MH062512
Pays : United States
Organisme : NIMH NIH HHS
ID : R21 MH076651
Pays : United States
Références
PLoS Curr. 2018 Aug 31;10:
pubmed: 30258698
J Neurovirol. 2002 Dec;8 Suppl 2:91-6
pubmed: 12491158
Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):13588-93
pubmed: 23898208
J Neurosci Res. 2001 Nov 1;66(3):510-6
pubmed: 11746370
Acta Paediatr. 2007 May;96(5):644-7
pubmed: 17376185
Expert Rev Mol Diagn. 2017 Aug;17(8):761-770
pubmed: 28598205
PLoS One. 2013 Sep 20;8(9):e75091
pubmed: 24073237
J Infect Dis. 2013 Jun 1;207(11):1703-12
pubmed: 23460748
FASEB J. 2011 Nov;25(11):3896-905
pubmed: 21828286
Acta Neurol Scand. 2017 Jan;135(1):34-56
pubmed: 26991855
Eur J Epidemiol. 2011 Mar;26(3):251-2; author reply 252
pubmed: 21442261
J Neurol. 2007 Aug;254(8):1026-32
pubmed: 17420923
Acta Paediatr. 2007 Apr;96(4):487-91
pubmed: 17306009
Exp Gerontol. 2010 Jan;45(1):30-40
pubmed: 19853650
Alzheimers Res Ther. 2018 Jan 11;10(1):3
pubmed: 29368621
Neurology. 2015 Jun 2;84(22):2247-57
pubmed: 25934855
Blood. 2001 Jan 15;97(2):352-8
pubmed: 11154208
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2017 Sep;161(3):286-295
pubmed: 28947837
J Neurovirol. 2013 Dec;19(6):550-6
pubmed: 24277437
J Immunol. 1999 Sep 1;163(5):2953-9
pubmed: 10453044
Front Mol Neurosci. 2017 May 29;10:163
pubmed: 28611588
Neurology. 2007 Oct 30;69(18):1789-99
pubmed: 17914061
Clin Neuropsychol. 2004 May;18(2):234-48
pubmed: 15587671
J Infect Dis. 2007 Jun 15;195(12):1774-8
pubmed: 17492593
Neurology. 2007 Oct 9;69(15):1536-41
pubmed: 17923616
J Neurovirol. 2018 Feb;24(1):28-40
pubmed: 29063514
PLoS One. 2014 Dec 26;9(12):e116081
pubmed: 25541953
J Acquir Immune Defic Syndr. 2015 May 1;69(1):29-35
pubmed: 25622053
J Cell Physiol. 2008 Jul;216(1):128-34
pubmed: 18247371
J Virol. 2004 Mar;78(5):2586-90
pubmed: 14963162
PLoS One. 2014 Feb 11;9(2):e88591
pubmed: 24523921
Nat Rev Neurol. 2018 Oct;14(10):577-589
pubmed: 30171200
Neurodegener Dis. 2007;4(2-3):185-94
pubmed: 17596713
J Infect Dis. 2002 Dec 1;186 Suppl 2:S193-8
pubmed: 12424697
J Neurol Neurosurg Psychiatry. 2019 Aug;90(8):870-881
pubmed: 30967444
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
J Neural Transm Suppl. 1998;53:223-35
pubmed: 9700660